A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colorectal Adenocarcinoma
- Head and Neck Cancer
- Metastatic Solid Tumor
- Recurrent Solid Tumor
- Solid Tumor, Adult
- Squamous Cell Carcinoma of Head and Neck
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04474470
- Collaborators
- Not Provided
- Investigators
- Study Director: Michael Schickler, PhD TyrNovo Ltd.